Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2014
06/26/2014WO2014095485A1 Silymarin aqueous formulation
06/26/2014WO2014095088A1 Egfr targeted therapy of neurological disorders and pain
06/26/2014WO2014095020A1 Improved platelet aggregation inhibition by means of a combination of nsaids and resveratrol or analogs thereof
06/26/2014WO2014094840A1 Use of pidotimod to treat psoriasis
06/26/2014WO2014094839A1 Use of pidotimod to treat atopic dermatitis
06/26/2014WO2014094783A1 Novel polymorphs of lnnt
06/26/2014WO2014094664A1 Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
06/26/2014WO2014094645A1 Rna interference preparation for curing hbv
06/26/2014WO2014094544A1 Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
06/26/2014WO2014094528A1 Compounds and methods for the treatment of cd20 positive diseases
06/26/2014WO2014094527A1 Compounds and methods for the treatment of erb b2/neu positive diseases
06/26/2014WO2014094370A1 6,8-substituted naringenin derivative and use thereof
06/26/2014WO2014094357A1 Heterocyclic nuclear hormone receptor modulators
06/26/2014WO2014094355A1 Compounds and methods for the treatment of egfr positive diseases
06/26/2014WO2014094353A1 Maytansinoid derivatives
06/26/2014WO2014094178A1 Radiosensitizer compounds for use in combination with radiation
06/26/2014WO2014094176A1 Uses and methods for the treatment of liver diseases or conditions
06/26/2014WO2014094087A1 Polymer nanoparticles containing amitraz and/or fluazuron, production method, formulation and uses
06/26/2014WO2014094043A1 Methods of generating cells with multilineage potential
06/26/2014WO2014094032A1 Polymorph
06/26/2014WO2014070016A3 Synbiotics combination for brain improvement
06/26/2014WO2014068327A3 Agents for the prevention and/or treatment of central nervous system damage
06/26/2014WO2014066127A3 High pufa oils for industrial applications
06/26/2014WO2014062878A3 Treatment of prostate cancer with tor kinase inhibitors
06/26/2014WO2014062697A3 Drug delivery conjugates containing unnatural amino acids and methods for using
06/26/2014WO2014057407A3 Compositions and methods for treatment of diabetes and prediabetes
06/26/2014WO2014055977A3 Modulation of branched amino acid concentrations
06/26/2014WO2014055644A3 Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay
06/26/2014WO2014054978A3 Stable combined solution of fenoterol hydrobromide and ipratropium bromide
06/26/2014WO2014047110A3 Substituted alkyl diaryl derivatives, methods of preparation and uses
06/26/2014WO2014045046A3 Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
06/26/2014WO2014039964A3 Compounds and methods for modulating vascular injury
06/26/2014WO2014033437A3 Nicotine composition
06/26/2014WO2014026013A3 Methods for maintaining or improving health, well-being and/or a physiological function in a subject
06/26/2014WO2013156871A3 Thromboxane receptor antagonists
06/26/2014WO2012100142A3 Treatments for retinal disorders
06/26/2014US20140180224 Composition, device and method for delayed and sustained release of brain energy molecules
06/26/2014US20140180223 Transparent transdermal nicotine delivery devices
06/26/2014US20140180098 Tissue Penetrating Catheters Having Integral Imaging Transducers and Their Methods of Use
06/26/2014US20140179877 Macromolecule conjugate
06/26/2014US20140179800 Inhibition of the Survival of Bladder Cancer by Cyclohexenone Compounds from Antrodia Camphorata
06/26/2014US20140179799 Small molecule modulators of microrna-34a
06/26/2014US20140179798 N1,n4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof
06/26/2014US20140179797 Composition for Administering an NMDA Receptor Antagonist to a Subject
06/26/2014US20140179794 Levomilnacipran-based drug for functional recovery after acute neurological events
06/26/2014US20140179793 Methods of treating neurodegeneration caused by iron accumulation in the brain comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179792 Method of treating lewy body syndrome with comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179791 Method of treating progressive supranuclear palsy comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179790 Method of treating traumatic brain injury/head injury comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179789 Methods of treating huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179788 Method of pre-treating patients for stroke comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179787 Method of treating spinal cord injury comprising administering metal chelators to the upper one-third of the nasal cavity
06/26/2014US20140179786 Treatment of Alzheimer's Disease Using Tolfenamic Acid
06/26/2014US20140179785 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
06/26/2014US20140179783 Citrulline-containing beverage
06/26/2014US20140179782 Neurogenesis screening method and uses thereof
06/26/2014US20140179781 Eicosapentaenoic acid (epa) formulations
06/26/2014US20140179780 Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating tlr- or il-6-mediated diseases
06/26/2014US20140179778 Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
06/26/2014US20140179777 Taste-masked docusate compositions
06/26/2014US20140179775 Neurogenesis screening method and uses thereof
06/26/2014US20140179773 Method for the treatment of heart related disorders in nafld patients
06/26/2014US20140179772 Anti-Malarial Pharmaceutical Composition
06/26/2014US20140179762 METHODS AND COMPOSITIONS REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS
06/26/2014US20140179761 Targeting lipids
06/26/2014US20140179760 In vivo production of small interfering rnas that mediate gene silencing
06/26/2014US20140179749 Formulations of enzalutamide
06/26/2014US20140179745 Topical ophthalmological pharmaceutical composition containing regorafenib
06/26/2014US20140179744 Synergistic combinations of pi3k- and mek-inhibitors
06/26/2014US20140179742 Compositions for killing or preventing the growth of microbes
06/26/2014US20140179741 Use of chelators of divalent cations to promote nerve regeneration
06/26/2014US20140179740 Stable liquid remifentanil formulations
06/26/2014US20140179739 Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
06/26/2014US20140179734 Adhesive skin patch containing serotonin receptor antagonist drug
06/26/2014US20140179733 Diazole amides
06/26/2014US20140179731 Tacrolimus For Improved Treatment Of Transplant Patients
06/26/2014US20140179729 Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
06/26/2014US20140179728 Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
06/26/2014US20140179727 Methods for treating pruritus
06/26/2014US20140179726 Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
06/26/2014US20140179721 Solid pharmaceutical dosage form
06/26/2014US20140179717 Use of PDE7 Inhibitors for the Treatment of Movement Disorders
06/26/2014US20140179712 Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
06/26/2014US20140179711 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
06/26/2014US20140179710 Antiviral salts
06/26/2014US20140179709 Antiviral agents
06/26/2014US20140179707 Novel ergoline derivatives and uses thereof
06/26/2014US20140179703 Concentrated methotrexate solutions
06/26/2014US20140179700 Methods of treating hemoglobinopathies
06/26/2014US20140179698 Selective protein kinase inhibitors
06/26/2014US20140179693 Methods for treating vascular leak syndrome
06/26/2014US20140179690 Fused aminodihydrothiazine derivatives
06/26/2014US20140179689 Novel rho kinase inhibitors and methods of use
06/26/2014US20140179683 Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof
06/26/2014US20140179679 Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
06/26/2014US20140179672 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
06/26/2014US20140179665 Hepatitis b antiviral agents
06/26/2014US20140179662 Pharmaceutically active disubstituted triazine derivatives
06/26/2014US20140179659 Method for suppressing surgical site infection and column to be used for the method
06/26/2014US20140179658 Methods and compositions for stimulation and enhancement of regeneration of tissues
1 ... 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 ... 7860